Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
NEOMYCIN SULFATE
Cross Vetpharm Group Limited
QA07AA01
NEOMYCIN SULFATE
400 Milligram
Oral Powder
POM: Prescription Only Medicine as defined in relevant national legislation
Bovine
neomycin
Antibacterial
Authorised
2007-01-22
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Hyspan 400mg Oral Powder 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 100g sachet contains: ACTIVE SUBSTANCE Neomycin Sulphate 400mg For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Oral powder. White to off-white free-flowing powder. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Calves. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of scour in calves mainly due to Escherichia coli and Salmonella. Specially formulated to combat infection, dehydration and loss of electrolytes. 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to the active ingredients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Withdraw all milk and milk replacer from scouring animals. I R I S H M E D I C I N E S B O A R D ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _0_ _6_ _/_ _0_ _9_ _/_ _2_ _0_ _1_ _2_ _C_ _R_ _N_ _ _ _7_ _0_ _1_ _3_ _3_ _1_ _5_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Withdraw all milk and milk replacer from scouring animals. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS None. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) Non Read the complete document